Baidu
map

Prostate Cancer P D:约翰·霍普金斯积极监控群体PTEN状态评估

2018-10-14 AlexYang MedSci原创

格林森评分6(GS6)前列腺癌男性中,那些最初通过积极监控(AS)来进行治疗的多达一半的患者都需要确定性的治疗,通常是由于跟踪调查期间肿瘤等级的重新界定。最近,有研究人员调查了患有GS6癌症且进行AS的男性患者,活检时的PTEN状态和随后的临床病理结果。研究人员在约翰·霍普金斯AS群体中进行了案例-对照研究,这些患者诊断的活检组织可以用于免疫组化(IHC)染色,并在所有的患者中,利用遗传学确定的方

格林森评分6(GS6)前列腺癌男性中,那些最初通过积极监控(AS)来进行治疗的多达一半的患者都需要确定性的治疗,通常是由于跟踪调查期间肿瘤等级的重新界定。最近,有研究人员调查了患有GS6癌症且进行AS的男性患者,活检时的PTEN状态和随后的临床病理结果。

研究人员在约翰·霍普金斯AS群体中进行了案例-对照研究,这些患者诊断的活检组织可以用于免疫组化(IHC)染色,并在所有的患者中,利用遗传学确定的方法对IHC进行了PTEN评估。研究发现,在67名具有充足的组织案例中,31名男性经历了早期的重鉴定,36名男性经历了极端的重新鉴定。研究人员利用案例与65名对照进行了比较,从而用于评估。在起始的前列腺癌活检中,与对照相比,案例男性年纪更大(平均年龄67 vs. 65, p?=?0.024),并且满足低风险标准的可能性更小(64 vs 79%, p?=?0.042)。尽管不显著,PTEN的缺失在65名对照中的1名(1.5%)中观察到,而在案例中为67名中具有6个(9%)(p?=?0.062)。

最后,研究人员指出,PTEN功能丧失在所召集的AS GS6前列腺癌患者中是罕见的。尽管如此,PTEN功能丧失在经历早期或者极端重新鉴定倾向更高等级的患者中要比对照更高。在更大的群体中的进一步研究可能会更高的阐释PTEN在AS患者选择中的作用。

原始出处:

Jeffrey J. Tosoian, Liana B. Guedes, Carlos L. Morais et al. PTEN status assessment in the Johns Hopkins active surveillance cohort. Prostate Cancer P D. 02 Oct 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791549, encodeId=d1781e91549cf, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 05 23:05:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804505, encodeId=c712180450595, content=<a href='/topic/show?id=acbce7297b0' target=_blank style='color:#2F92EE;'>#约翰·霍普金斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77297, encryptionId=acbce7297b0, topicName=约翰·霍普金斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Nov 06 02:05:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716999, encodeId=16311e1699918, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Fri Sep 27 20:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315926, encodeId=3bd7131592636, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364399, encodeId=98a51364399cf, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602064, encodeId=4ccb1602064c3, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617677, encodeId=8387161e677f3, content=<a href='/topic/show?id=6287e512359' target=_blank style='color:#2F92EE;'>#积极监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75123, encryptionId=6287e512359, topicName=积极监控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc019794125, createdName=ms5106640509429053, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791549, encodeId=d1781e91549cf, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 05 23:05:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804505, encodeId=c712180450595, content=<a href='/topic/show?id=acbce7297b0' target=_blank style='color:#2F92EE;'>#约翰·霍普金斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77297, encryptionId=acbce7297b0, topicName=约翰·霍普金斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Nov 06 02:05:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716999, encodeId=16311e1699918, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Fri Sep 27 20:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315926, encodeId=3bd7131592636, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364399, encodeId=98a51364399cf, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602064, encodeId=4ccb1602064c3, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617677, encodeId=8387161e677f3, content=<a href='/topic/show?id=6287e512359' target=_blank style='color:#2F92EE;'>#积极监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75123, encryptionId=6287e512359, topicName=积极监控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc019794125, createdName=ms5106640509429053, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1791549, encodeId=d1781e91549cf, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 05 23:05:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804505, encodeId=c712180450595, content=<a href='/topic/show?id=acbce7297b0' target=_blank style='color:#2F92EE;'>#约翰·霍普金斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77297, encryptionId=acbce7297b0, topicName=约翰·霍普金斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Nov 06 02:05:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716999, encodeId=16311e1699918, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Fri Sep 27 20:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315926, encodeId=3bd7131592636, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364399, encodeId=98a51364399cf, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602064, encodeId=4ccb1602064c3, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617677, encodeId=8387161e677f3, content=<a href='/topic/show?id=6287e512359' target=_blank style='color:#2F92EE;'>#积极监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75123, encryptionId=6287e512359, topicName=积极监控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc019794125, createdName=ms5106640509429053, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]
    2019-09-27 xjy13
  4. [GetPortalCommentsPageByObjectIdResponse(id=1791549, encodeId=d1781e91549cf, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 05 23:05:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804505, encodeId=c712180450595, content=<a href='/topic/show?id=acbce7297b0' target=_blank style='color:#2F92EE;'>#约翰·霍普金斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77297, encryptionId=acbce7297b0, topicName=约翰·霍普金斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Nov 06 02:05:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716999, encodeId=16311e1699918, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Fri Sep 27 20:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315926, encodeId=3bd7131592636, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364399, encodeId=98a51364399cf, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602064, encodeId=4ccb1602064c3, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617677, encodeId=8387161e677f3, content=<a href='/topic/show?id=6287e512359' target=_blank style='color:#2F92EE;'>#积极监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75123, encryptionId=6287e512359, topicName=积极监控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc019794125, createdName=ms5106640509429053, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]
    2018-10-16 xiaogang317
  5. [GetPortalCommentsPageByObjectIdResponse(id=1791549, encodeId=d1781e91549cf, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 05 23:05:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804505, encodeId=c712180450595, content=<a href='/topic/show?id=acbce7297b0' target=_blank style='color:#2F92EE;'>#约翰·霍普金斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77297, encryptionId=acbce7297b0, topicName=约翰·霍普金斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Nov 06 02:05:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716999, encodeId=16311e1699918, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Fri Sep 27 20:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315926, encodeId=3bd7131592636, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364399, encodeId=98a51364399cf, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602064, encodeId=4ccb1602064c3, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617677, encodeId=8387161e677f3, content=<a href='/topic/show?id=6287e512359' target=_blank style='color:#2F92EE;'>#积极监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75123, encryptionId=6287e512359, topicName=积极监控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc019794125, createdName=ms5106640509429053, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]
    2018-10-16 lsndxfj
  6. [GetPortalCommentsPageByObjectIdResponse(id=1791549, encodeId=d1781e91549cf, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 05 23:05:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804505, encodeId=c712180450595, content=<a href='/topic/show?id=acbce7297b0' target=_blank style='color:#2F92EE;'>#约翰·霍普金斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77297, encryptionId=acbce7297b0, topicName=约翰·霍普金斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Nov 06 02:05:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716999, encodeId=16311e1699918, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Fri Sep 27 20:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315926, encodeId=3bd7131592636, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364399, encodeId=98a51364399cf, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602064, encodeId=4ccb1602064c3, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617677, encodeId=8387161e677f3, content=<a href='/topic/show?id=6287e512359' target=_blank style='color:#2F92EE;'>#积极监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75123, encryptionId=6287e512359, topicName=积极监控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc019794125, createdName=ms5106640509429053, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]
    2018-10-16 sunylz
  7. [GetPortalCommentsPageByObjectIdResponse(id=1791549, encodeId=d1781e91549cf, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 05 23:05:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804505, encodeId=c712180450595, content=<a href='/topic/show?id=acbce7297b0' target=_blank style='color:#2F92EE;'>#约翰·霍普金斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77297, encryptionId=acbce7297b0, topicName=约翰·霍普金斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Nov 06 02:05:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716999, encodeId=16311e1699918, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Fri Sep 27 20:05:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315926, encodeId=3bd7131592636, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364399, encodeId=98a51364399cf, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602064, encodeId=4ccb1602064c3, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617677, encodeId=8387161e677f3, content=<a href='/topic/show?id=6287e512359' target=_blank style='color:#2F92EE;'>#积极监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75123, encryptionId=6287e512359, topicName=积极监控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc019794125, createdName=ms5106640509429053, createdTime=Tue Oct 16 12:05:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]

相关资讯

FDA认定rucaparib作为前列腺癌突破性疗法资格

Clovis Oncology公司10月2日宣布,Rubraca (rucaparib)用于单药治疗既往接受过抗雄激素受体疗法以及紫杉烷类化疗的BRCA1/2+成人转移性去势抵抗前列腺癌(mCRPC)已被FDA授予突破性疗法资格。rucaparib之前也被FDA授予过单药治疗特定晚期卵巢癌患者的突破性疗法资格,并且在2016年12月19日被FDA批准用于单药治疗既往接受过两种以上化疗的BRCA突变

Sci Rep:不同格林森评分前列腺癌中类固醇激素受体和基质细胞标记表达比较

抗血管生成和免疫调节药物最近的发展表明了肿瘤微环境(TME)在癌症研究中越来越重要。最近,有研究人员通过比较不同GS组中类固醇激素受体的组织表达情况、癌症激活成纤维细胞(CAF)标记和血管密度情况,调查了格林森评分(GS)与TME之间的相关性。匹配的患者群体组成了不同的GS分组(6-7-8)。研究人员利用6个样本/患者的组织芯片进行免疫组化染色。研究人员对染色的片子进行数字化,并对基质和上皮进行选

Oncogene:肌醇聚磷酸酯4-磷酸酶II型调控雄激素受体的活性

晚期前列腺癌中AR的激活和转录重组总是与2个肿瘤抑制因子,INPP4B和PTEN的功能丧失同时发生,上述2个肿瘤抑制因子在人类和小鼠前列腺上皮中高表达。虽然AR信号通过PTEN的调控已经被多个研究组阐释,但是否INPP4B功能的丧失影响AR的活性仍旧不清楚。最近,有研究人员利用前列腺癌细胞系,展示了INPP4B能够调控AR转录活性和致瘤信号途径Akt和PKC。在前列腺癌患者群体中基因表达的分析表明

Lancet oncol:激素疗法的顺序和放射照射的面积对前列腺癌患者预后的影响

NRG/RTOG 9413研究显示,与仅对前列腺进行放射治疗(PORT)联合新辅助激素治疗(NHT)、全骨盆放疗(WPRT)联合辅助激素治疗(AHT)和PORT联合AHT相比,WPRT联合NHT可提高中高风险的局限性前列腺癌患者的无进展存活率。现Prof Mack Roach等人对激素疗法的顺序和放射照射的面积对前列腺癌患者预后的影响进行研究。研究人员设计了一个2x2的阶乘研究,以激素治疗顺序和放

Sci Rep:包含活性基质前列腺癌组织的代谢和转录组分析

活性基质是一种组织特性,通常在前列腺癌的肿瘤微环境中观察到,并且与恶性肿瘤相关。最近,有研究人员在完全相同的前列腺癌组织样本中,检测了活性氧基质包含物中差异表达的基因和代谢物质。研究人员利用组织病理学评估了来自43名前列腺切除术后患者的108份冷冻的前列腺癌样本活性氧基质。研究人员在部分样本中利用高分辨率魔角旋转磁共振光谱(HR-MAS MRS)he RNA芯片分别分析了代谢物(n=85)和转录组

Oncogene:PDZ结合激酶和雄激素受体相互反馈能够驱使前列腺癌发生

阐释雄激素受体(AR)活性增加和随后恶性前列腺癌(PrCa)发展的潜在的机制在发展新的理论方面是非常关键的。最近,有研究人员利用系统生物学的方法,分析了AR调控的蛋白组,并坚定了一个新的AR调控的蛋白-PDZ结合激酶(PBK),该蛋白能够在PrCa中调节全程AR和AR变异体的活性。PBK在恶性PrCa中的过表达与早期生化复发和不良临床结果相关。除了碳末端配体结合区域,PBK还可以与AR的氮末端反式

Baidu
map
Baidu
map
Baidu
map